Click here to Register

2017 Agenda

  • 8:00 am

  • Registration & Breakfast

  • 8:45 am

  • Welcome Message


    Dr Robert Langer

    David H. Koch Institute Professor, MIT

  • 8:50 am

  • Chair’s Opening Remarks and A Year in Review


    Barbara Lueckel, PhD

    Head of Research and Technologies Partnering, Roche

  • 9:15 am

  • Bioinspirationalist Keynote

    Dr Jeff Karp is a world leader in drug delivery, stem cell therapeutics, and tissue adhesives. He is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology.

    Dr Karp’s work has been selected as one of Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine” and in 2013 the Institute for Chemical Engineers awarded one of his technologies the Most Innovative Product of the Year.  His work has been recognized by various media outlets including CNN, ABC, Fox News, MSNBC, National Geographic, Popular Science, and the Washington Post. Several of his technologies have formed the foundation for products on the market or under development and for the launch of companies including: Gecko BiomedicalSkintifiqueFrequency Therapeutics, and Alivio Therapeutics.


    Jeffrey Karp, PhD

    Director of the Laboratory for Accelerated Medical Innovation, Brigham and Women’s Hospital

  • 9:50 am

  • Viewpoints on Drug Delivery Partnering Panel: The Voices of Big Pharma, Specialty/Generic Pharma, and Drug Delivery Innovators

    The intent of this panel is to compare and contrast the different needs of and processes used by big pharma and specialty/generic pharma in scouting, and acquiring/licensing and integrating drug delivery technologies.

    Moderator:
    Colin Minchom, PhD
    Sr Director, Pharmaceutical Sciences, Shire

    Panelists:
    Robert Bloder
    VP, Global Business Development, Apotex


    Sesha Neervannan, PhD

    Sr VP, Pharmaceutical Development, Allergan

    Aaron Schwartz
    Director, R&D Innovation Sourcing, Novo Nordisk

    Specialty/Generic Pharma panelist TBA

  • 10:30 am

  • Morning Networking Session

  • 11:15 am

  • Fireside Industry Partnership ChatsAdvancing Drug Delivery to Benefit Patients: A Camurus Case Study & Partnership Chat

    Featuring:
    Grégoire Schwach
    Head of Drug Delivery, F. Hoffmann-La Roche Ltd

    Fredrik Joabsson
    VP, Business Development and Alliance Management, Camurus

    In this session, Camurus will introduce the FluidCrystal technology and describe the development history of the two most advanced programs, from initiation to present.  The company will also discuss major milestones achieved as well as partner selection and deal structures.

    In the second part of this session, Roche and Camurus will discuss:

    • Selection of the right molecules for lead programs, from a business and technical perspective
    • Importance of partnering to advance the technology
    • Partnering with a multinational company (Novartis) vs. specialty company (Braeburn) – what were the strategic reasons for doing so and what are the differences in working with each?
    • Key lessons learned as the technology matures and programs advance through scale-up and clinical development
  • 11:45 am

  • Panel: Designing Connected Health Solutions to Drive Outcomes

    Connected health continues to be a hot topic for our industry, and the potential remains attractive and compelling. The challenge of delivering value through connected health remains significant, complicated by an evolving regulatory landscape and a volatile reimbursement dynamic. Panelists will discuss their approaches to overcoming the challenges of creating connected health solutions which are adopted by the market.

    Led by:

    Michael Ratigan

    VP, Sales, Phillips-Medisize


    Anand Subramony, PhD

    VP, Novel Product Technologies, MedImmune

  • 12:15 pm

  • Non-Invasive Drug Delivery: Overview and Emerging Trends


    Tugrul Karali, PhD

    President and Founder, PharmaCircle

  • 12:35 pm

  • Lunch & Partnering Meetings

  • 1:55 pm
    - 6:00 pm

  • Drug Delivery Technology Presentations in Three Tracks, 6 sessions

    Refreshment Break 4:00 pm – 4:15 pm

    Presenting Companies to Date:

    • Track 1A: Injectable Technologies

      2:00 pm- 4:00 pm

      Companies will present  sustained release, targeting, and drug-conjugate technologies, as well as pre-filled syringes, vials and similar technologies.

      Moderator:


      Matthew Burke, PhD

      Head of Drug Delivery, GSK

      Presenting Companies:
      2:00 pm
      Halozyme Therapeutics, Inc

      2:15 pm
      Enable Injections

      2:45 pm
      Phion Therapeutics Ltd

      3:00 pm
      Oakwood Labs

      3:15 pm
      Serina Therapeutics

      3:30 pm
      Innocore Pharmaceuticals

      3:45 pm
      Credence MedSystems

    • Refreshment Break

      4:00 pm- 4:15 pm

    • Track 1B: Injectable Technologies

      4:15 pm- 6:00 pm

      Companies will present  sustained release, targeting, and drug-conjugate technologies, as well as pre-filled syringe, vial and similar injection technologies

      Moderator:


      Ulrich Bruggemann

      Head Academics and Innovation, Global Medical Devices Development, Sanofi US

      Presenting Companies:
      4:15 pm
      Gerresheimer Medical Systems

      4:30 pm
      Mitsubishi Gas Chemical

      4:45 pm
      Balda/Stevanato Group

      5:00 pm
      pSivida Corporation

      5:15 pm
      Cristal Therapeutics

      Two more spots available

    • Track 2A: Oral Delivery Technologies

      2:00 pm- 4:00 pm

      Companies will present oral delivery technologies such as controlled release, modified release, and bioavailability and/or solubility enhancing technologies.

      Moderator:


      René Holm, PhD

      Head and Scientific Director, Drug Product Development, Liquids and Parenterals, Janssen

      Presenting Companies:
      TBA

    • Refreshment Break

      4:00 pm- 4:15 pm

    • Track 2B: Non-Injectable Technologies: Transdermal & Transmucosal

      4:15 pm- 6:00 pm

      Companies will present transdermal, pulmonary, nasal, ophthalmic, and other mucosal delivery technologies.

      Moderator:


      Robert Saklatvala, PhD

      Director, Discovery Pharmaceutical Sciences, Merck

      Presenting Companies:
      4:15 pm
      LayerBio

      More TBA

    • Track 3A: Device Technologies

      2:00 pm- 4:00 pm

      Companies will present various technologies such as needle-free devices, autoinjectors, patch pumps/wearable injectors, and other novel delivery devices.

      Moderator:


      Mathias Romacker

      Senior Director, Device Strategy, Pfizer

      Presenting Companies:
      2:00 pm
      Insulet Corporation

      2:15 pm
      Portal Instruments

      2:45 pm
      West Pharmaceutical Services

      3:00 pm
      Bespak

      3:15pm
      Sensile Medical

      3:30 pm
      BioCorp

      3:45 pm
      Nemera

    • Refreshment Break

      4:00 pm- 4:15 pm

    • Track 3B: Device Technologies

      4:15 pm- 6:00 pm

      Companies will present various technologies such as needle-free devices, autoinjectors, patch pumps/wearable injectors, and other novel delivery devices.

      Moderator:

      Justin Wright
      Justin Wright, PhD

      VP, Drug Delivery Innovation, DDR&D Technology, Eli Lilly & Co

      Presenting Companies:
      4:15 pm
      BD Medical

      4:30 pm
      Cambridge Design

      4:45 pm
      Vernay

      5:00 pm
      DALI Medical Devices

      Three more spots available

  • 6:00 pm

  • End of Day One & Annual Networking Reception

2017 Agenda

  • 8:00 am

  • Breakfast

  • 8:45 am

  • Chair’s Welcome Address


    Barbara Lueckel, PhD

    Head of Research and Technologies Partnering, Roche

  • 8:45 am

  • CEO Keynote


    Lars Rebien Sorensen

    Former President and CEO, Novo Nordisk

    Ranked as the world’s top performing CEO in 2015 and 2016 by Harvard Business Review

  • 9:20 am

  • Nanotechnology Keynote

    Omid Farokhzad
    Omid Farokhzad, MD

    Professor and Director, Center for Nanomedicine, Brigham and Women’s Hospital

    Named One of the 100 Most Influential People in Biotech by Scientific American

  • 9:50 am

  • Panel: Utilizing a Device Platform Technology across Multiple Therapeutic Categories

    Most pharma and biotech companies realize the need and benefit of having a platform device technology. The challenge then becomes figuring out how to utilize the device to deliver different types of drugs for various indications such as rheumatoid arthritis, cancer, and rare diseases.

    Moderator:
    Paul Jansen
    Paul Jansen

    Former Associate VP, Sanofi, and current Board Member, Haselmeier

    Panelists:
    Donna French, PhD
    Sr Director, PTDU Device Development, Genentech


    Michael Graffeo

    VP, Business Development, Drug Delivery, Insulet


    Srini Sridharan, PhD

    Group Director, Materials Science & Engineering, BMS


    Anand Subramony, PhD

    VP, Novel Product Technologies, MedImmune

  • 10:30 am

  • Morning Networking Session

  • 11:15 am

  • 7th Annual Company Spotlights

    In this session, we highlight three companies to discuss their partnering philosophy, current needs and scouting interests, as related to drug delivery.

    Boehringer Ingelheim

    Keith Horspool, PhD

    VP, Pharmaceutics

    Novartis Institutes for Biomedical Research

    Manuel Sanchez-Felix, PhD

    Senior Fellow, Novel Drug Delivery Technologies

    Novo Nordisk
    Aaron Schwartz
    Director of R&D, Innovation Sourcing

  • 12:15 pm

  • Open Session

  • 12:30 pm

  • Luncheon

  • 1:40 pm

  • Current and Emerging Drug Delivery Needs in Oncology

    Due to the increasing number of parenteral biologic therapies that are administered intravenously, there is a need for improved delivery formulations to reduce the overall burden on the healthcare system.  There is keen interest in technologies that enable IV formulations to be self-administered subcutaneously, to reduce treatment complexity and markedly reduce treatment costs and healthcare resources.

    Led by:

    Beate Bittner, PhD

    Product Optimization Director, Roche

    Panelists:
    Christina Braden-Moore
    Marketing Director, Pharmaceutical Systems, BD Medical


    Ulrich Bruggemann

    Head Academics and Innovation, Global Medical Devices Development, Sanofi US

    Declan Reilly
    Section Head, Device Engineering, Device Development PTDE-D, Roche

    Andrew J Yee, MD
    Medical Oncologist, Massachusetts General Hospital Cancer Center

    Additional panelists TBA

  • 2:30 pm

  • DDS Technology Soapbox

    sponsored by

    This session features five minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

    Moderator:

    Patrick Lim Soo, PhD

    Senior Principal Scientist, Novel Delivery Technologies, Pfizer

    Presenters:
    Pfizer

    Cocoon Biotech Inc

    Additional presenters TBA

  • 3:30 pm

  • Panel: Hitting the "Reset" Button on Direct-to-CNS Delivery

    The expert panel will address the scientific and business challenges and opportunities in this space. Panelists will discuss the difficult nature of providing therapies for diseases of the CNS, covering both device and chemistry-enabled technologies.  They will also address questions such as:  Can devices take us where chemistry has not? What advances are being made in the field of chemistry conjugation technologies?  Why is intrathecal, intracerebroventricular and intraparenchymal delivery relevant for CNS and other therapeutic categories?  Finally, the panel will talk about lessons learned, particularly with regard to scientific vs. business rationale.

    Introduction by:

    PJ Anand
    Founder and CEO, Alcyone Lifesciences

    Moderator:

    Lisa Shafer, PhD

    Senior Director, New Devices and Bioelectronic Technologies, Teva

    Panelists:
    Krystof Bankiewicz, MD, PhD
    Director, Interventional Neuro Center, UCSF

    Keith Hildebrand, PhD
    Senior Principal Scienist, Targeted Drug Delivery, Medtronic

    Mikhail Papisov, PhD
    Director, Molecular Pharmacology & Pharmacological Imaging, MGH


    Lamya Shihabuddin, PhD

    Cluster Head, Neuro Rare Diseases, Shire

  • 4:30 pm

  • Conference Concludes